Eli Lilly and Co (LLY)

LLY (NYSE:Drugs) EQUITY
$71.39
neg -0.03
-0.04%
Today's Range: 70.43 - 71.73 | LLY Avg Daily Volume: 4,753,500
Last Update: 02/12/16 - 3:29 PM EST
Volume: 3,870,730
YTD Performance: 0.00%
Open: $71.50
Previous Close: $71.42
52 Week Range: $68.31 - $92.85
Oustanding Shares: 1,108,076,549
Market Cap: 80,967,153,435
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 7
Moderate Buy 0 0 0 0
Hold 3 3 3 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.50 1.50 1.83
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
0.00 33.00 27.18
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue -15.10 -0.19 -0.07
Net Income -49.00 -0.45 -0.18
EPS -48.50 -0.43 -0.17
Earnings for LLY:
EBITDA 4.71B
Revenue 19.62B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.81 $0.88 $3.53 $3.99
Number of Analysts 6 4 9 10
High Estimate $0.85 $0.90 $3.56 $4.28
Low Estimate $0.78 $0.86 $3.50 $3.03
Prior Year $0.87 $0.90 $3.43 $3.53
Growth Rate (Year over Year) -6.51% -2.50% 3.05% 12.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Jan 29, 2016 | 7:29 AM EST
LLY estimates were raised through 2017, Leerink Partners said. Company is facing lower tax rates. Outperform rating and new $96 price t...
Two significant, but subtle forces may threaten the group in the next 12 months.
Lack of volume is causing the exaggerated market moves, right now.
Aren't we being a bit too quick to write off 2016?
Bullish
Dec 07, 2015 | 7:38 AM EST
LLY was upgraded to Buy, Deutsche Bank said. $85 price target. Expect higher peak sales for solanezumab for Alzheimer's.
Whether it's winter coats or stocks, you have reasons for buying.

Columnist Conversations

Some pretty obvious selling in the FATMAN names vs the Nasdaq futures post regular session open. FATM...
You can see the time/price support on the daily chart of SPX below. It also shows you the next major decision ...
$185.80 Exhausted and a long weekend. Column up shortly Sold some IWM as well.
Rally showing some legs as we approached mid-day. Consumer doesn't look like recession is coming. Retail sal...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.